C3 glomerulopathy — understanding a rare complement-driven renal disease
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
The C3 glomerulopathies are a group of rare kidney diseases characterized by complement dysregulation occurring in the fluid phase and in the glomerular microenvironment, which results in prominent complement C3 deposition in kidney biopsy samples. The two major subgroups of C3 glomerulopathy — dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) — have overlapping clinical and pathological features suggestive of a disease continuum. Dysregulation of the complement alternative pathway is fundamental to the manifestations of C3 glomerulopathy, although terminal pathway dysregulation is also common. Disease is driven by acquired factors in most patients — namely, autoantibodies that target the C3 or C5 convertases. These autoantibodies drive complement dysregulation by increasing the half-life of these vital but normally short-lived enzymes. Genetic variation in complement-related genes is a less frequent cause. No disease-specific treatments are available, although immunosuppressive agents and terminal complement pathway blockers are helpful in some patients. Unfortunately, no treatment is universally effective or curative. In aggregate, the limited data on renal transplantation point to a high risk of disease recurrence (both DDD and C3GN) in allograft recipients. Clinical trials are underway to test the efficacy of several first-generation drugs that target the alternative complement pathway.This Review presents our current understanding of C3 glomerulopathy. Smith et al. discuss the histopathological diagnosis and the crucial pathogenic role of complement dysregulation. Genetic and acquired drivers of C3 glomerulopathy, potential biomarkers and available treatments are highlighted.Key pointsC3 glomerulopathies are rare diseases that share an underlying mechanism of complement dysregulation in the fluid phase and glomerular microenvironment.Diagnosis relies solely on renal biopsy immunofluorescence findings; light microscopy findings and complement biomarker profiles are heterogeneous.Acquired drivers, in the form of autoantibodies, are the abnormalities most frequently associated with complement dysregulation.Genetic variants in the C3, CFB, CFH, CFI and CFHR1–CFHR5 genes are potentially causal; both rare and common variants can coexist and are associated with susceptibility to disease.Convertase dysregulation is central to the pathogenesis of C3 glomerulopathy.Conditions such as post-infectious glomerulonephritis cannot be differentiated from C3 glomerulopathy by renal biopsy alone, which can confound early diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Goodship, T. H. J., Cook, H. T., Fakhouri, F., Fervenza, F. C., Frémeaux-Bacchi, V., Kavanagh, D., Nester, C. M., Noris, M., Pickering, M. C., Rodríguez de Córdoba, S., et al. (2017) · Kidney International · doi:10.1016/j.kint.2016.10.005 · Cited by 701
Self-citationPangburn, M. K., Schreiber, R. D., & Müller-Eberhard, H. J. (1977) · The Journal of experimental medicine · doi:10.1084/jem.146.1.257 · Cited by 684
C3 glomerulopathy: consensus report
Pickering, M. C., D'Agati, V. D., Nester, C. M., Smith, R. J., Haas, M., Appel, G. B., Alpers, C. E., Bajema, I. M., Bedrosian, C., Braun, M., et al. (2013) · Kidney International · doi:10.1038/ki.2013.377 · Cited by 653
Self-citationModulation of the alternative complement pathways by beta 1 H globulin.
Whaley, K., & Ruddy, S. (1976) · The Journal of experimental medicine · doi:10.1084/jem.144.5.1147 · Cited by 583
Servais, A., Noël, L.-H., Roumenina, L. T., Le Quintrec, M., Ngo, S., Dragon-Durey, M.-A., Macher, M.-A., Zuber, J., Karras, A., Provot, F., et al. (2012) · Kidney International · doi:10.1038/ki.2012.63 · Cited by 575
Membranoproliferative Glomerulonephritis — A New Look at an Old Entity
Sethi, S., & Fervenza, F. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1108178 · Cited by 565
Self-citationPickering, M. C., Cook, H. T., Warren, J., Bygrave, A. E., Moss, J., Walport, M. J., & Botto, M. (2002) · Nature Genetics · doi:10.1038/ng912 · Cited by 518
Self-citationComplement component C3 – The “Swiss Army Knife” of innate immunity and host defense
Ricklin, D., Reis, E. S., Mastellos, D. C., Gros, P., & Lambris, J. D. (2016) · Immunological Reviews · doi:10.1111/imr.12500 · Cited by 484
Self-citationMedicine, N. L. O. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989377 · Cited by 468
Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis
Bomback, A. S., Smith, R. J., Barile, G. R., Zhang, Y., Heher, E. C., Herlitz, L., Stokes, M. B., Markowitz, G. S., D’Agati, V. D., Canetta, P. A., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12901211 · Cited by 366
Self-citationGale, D. P., de Jorge, E. G., Cook, H. T., Martinez-Barricarte, R., Hadjisavvas, A., McLean, A. G., Pusey, C. D., Pierides, A., Kyriacou, K., Athanasiou, Y., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60670-8 · Cited by 327
Self-citationWu, J., Wu, Y.-Q., Ricklin, D., Janssen, B. J. C., Lambris, J. D., & Gros, P. (2009) · Nature Immunology · doi:10.1038/ni.1755 · Cited by 327
Self-citationServais, A., Frémeaux-Bacchi, V., Lequintrec, M., Salomon, R., Blouin, J., Knebelmann, B., Grünfeld, J.-P., Lesavre, P., Noël, L.-H., & Fakhouri, F. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.045328 · Cited by 291
Self-citationDimerization of complement factor H-related proteins modulates complement activation in vivo
Goicoechea de Jorge, E., Caesar, J. J. E., Malik, T. H., Patel, M., Colledge, M., Johnson, S., Hakobyan, S., Morgan, B. P., Harris, C. L., Pickering, M. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219260110 · Cited by 289
Self-citationA proposal for standardized grading of chronic changes in native kidney biopsy specimens
Sethi, S., D’Agati, V. D., Nast, C. C., Fogo, A. B., De Vriese, A. S., Markowitz, G. S., Glassock, R. J., Fervenza, F. C., Seshan, S. V., Rule, A., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.01.002 · Cited by 279
Self-citationHeinen, S., Hartmann, A., Lauer, N., Wiehl, U., Dahse, H.-M., Schirmer, S., Gropp, K., Enghardt, T., Wallich, R., Hälbich, S., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205641 · Cited by 272
Self-citationNew Approaches to the Treatment of Dense Deposit Disease
Smith, R. J. H., Alexander, J., Barlow, P. N., Botto, M., Cassavant, T. L., Cook, H. T., de Córdoba, S. R., Hageman, G. S., Jokiranta, T. S., Kimberling, W. J., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007030356 · Cited by 269
Self-citationC3 Glomerulopathy: Clinicopathologic Features and Predictors of Outcome
Medjeral-Thomas, N. R., O’Shaughnessy, M. M., O’Regan, J. A., Traynor, C., Flanagan, M., Wong, L., Teoh, C. W., Awan, A., Waldron, M., Cairns, T., et al. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04700513 · Cited by 256
Self-citationMeri, S., Koistinen, V, Miettinen, A., Törnroth, T., & Seppälä, I. J. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.4.939 · Cited by 223
Bomback, A. S., Santoriello, D., Avasare, R. S., Regunathan-Shenk, R., Canetta, P. A., Ahn, W., Radhakrishnan, J., Marasa, M., Rosenstiel, P. E., Herlitz, L. C., et al. (2018) · Kidney International · doi:10.1016/j.kint.2017.10.022 · Cited by 219
Self-citationEculizumab in the Treatment of Membranoproliferative Glomerulonephritis
Bomback, A. S. (2014) · Nephron Clinical Practice · doi:10.1159/000368592 · Cited by 216
Høgåsen, K., Jansen, J. H., Mollnes, T. E., Hovdenes, J., & Harboe, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117751 · Cited by 213
Sethi, S., Fervenza, F. C., Zhang, Y., Zand, L., Meyer, N. C., Borsa, N., Nasr, S. H., & Smith, R. J. H. (2013) · Kidney International · doi:10.1038/ki.2012.384 · Cited by 208
Self-citationToward a working definition of C3 glomerulopathy by immunofluorescence
Hou, J., Markowitz, G. S., Bomback, A. S., Appel, G. B., Herlitz, L. C., Barry Stokes, M., & D'Agati, V. D. (2014) · Kidney International · doi:10.1038/ki.2013.340 · Cited by 203
Self-citationSethi, S., Gamez, J. D., Vrana, J. A., Theis, J. D., Robert Bergen, H., Zipfel, P. F., Dogan, A., & Smith, R. J. H. (2009) · Kidney International · doi:10.1038/ki.2008.657 · Cited by 200
Self-citationC3 glomerulopathy–associated CFHR1 mutation alters FHR oligomerization and complement regulation
Tortajada, A., Yébenes, H., Abarrategui-Garrido, C., Anter, J., García-Fernández, J. M., Martínez-Barricarte, R., Alba-Domínguez, M., Malik, T. H., Bedoya, R., Pérez, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68280 · Cited by 197
Self-citationGlobal Analysis Reveals the Complexity of the Human Glomerular Extracellular Matrix
Lennon, R., Byron, A., Humphries, J. D., Randles, M. J., Carisey, A., Murphy, S., Knight, D., Brenchley, P. E., Zent, R., & Humphries, M. J. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013030233 · Cited by 194
Causes of Alternative Pathway Dysregulation in Dense Deposit Disease
Zhang, Y., Meyer, N. C., Wang, K., Nishimura, C., Frees, K., Jones, M., Katz, L. M., Sethi, S., & Smith, R. J. H. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07900811 · Cited by 188
Self-citationChauvet, S., Frémeaux-Bacchi, V., Petitprez, F., Karras, A., Daniel, L., Burtey, S., Choukroun, G., Delmas, Y., Guerrot, D., François, A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-737163 · Cited by 188
Iatropoulos, P., Noris, M., Mele, C., Piras, R., Valoti, E., Bresin, E., Curreri, M., Mondo, E., Zito, A., Gamba, S., et al. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.01.010 · Cited by 183
Self-citationOsborne, A. J., Breno, M., Borsa, N. G., Bu, F., Frémeaux-Bacchi, V., Gale, D. P., van den Heuvel, L. P., Kavanagh, D., Noris, M., Pinto, S., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701695 · Cited by 171
Self-citationEffectiveness of mycophenolate mofetil in C3 glomerulonephritis
Rabasco, C., Cavero, T., Román, E., Rojas-Rivera, J., Olea, T., Espinosa, M., Cabello, V., Fernández-Juarez, G., González, F., Ávila, A., et al. (2015) · Kidney International · doi:10.1038/ki.2015.227 · Cited by 170
Self-citationC3 Glomerulopathy: Ten Years' Experience at Mayo Clinic
Ravindran, A., Fervenza, F. C., Smith, R. J., Vriese, A. S. D., & Sethi, S. M. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.05.019 · Cited by 168
Self-citationNoris, M., & Remuzzi, G. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.03.040 · Cited by 159
Self-citationPickering, M. C., Warren, J. A., Rose, K. L., Carlucci, F., Wang, Y., Walport, M. J., Cook, H. T., & Botto, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601094103 · Cited by 159
Self-citationFactor H-related proteins determine complement-activating surfaces
Józsi, M., Tortajada, A., Uzonyi, B., Goicoechea de Jorge, E., & Rodríguez de Córdoba, S. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.008 · Cited by 144
Self-citationC3 glomerulopathy associated with monoclonal Ig is a distinct subtype
Ravindran, A., Fervenza, F. C., Smith, R. J., & Sethi, S. M. (2018) · Kidney International · doi:10.1016/j.kint.2018.01.037 · Cited by 136
Self-citationBlanc, C., Togarsimalemath, S. K., Chauvet, S., Quintrec, M. L., Moulin, B., Büchler, M., Jokiranta, T. S., Roumenina, L. T., Frémeaux‐Bacchi, V., & Dragon‐Durey, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402770 · Cited by 133
Rose, K. L., Paixao-Cavalcante, D., Fish, J., Manderson, A. P., Malik, T. H., Bygrave, A. E., Lin, T., Sacks, S. H., Walport, M. J., Cook, H. T., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32525 · Cited by 130
Self-citationA Hybrid CFHR3-1 Gene Causes Familial C3 Glomerulopathy
Malik, T. H., Lavin, P. J., Goicoechea de Jorge, E., Vernon, K. A., Rose, K. L., Patel, M. P., de Leeuw, M., Neary, J. J., Conlon, P. J., Winn, M. P., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012020166 · Cited by 130
Self-citationComplement factor H–related hybrid protein deregulates complement in dense deposit disease
Chen, Q., Wiesener, M. S., Eberhardt, H. U., Hartmann, A., Uzonyi, B., Kirschfink, M., Amann, K., Buettner, M., Goodship, T. H. J., Hugo, C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci71866 · Cited by 127
Self-citationMarinozzi, M. C., Roumenina, L. T., Chauvet, S., Hertig, A., Bertrand, D., Olagne, J., Frimat, M., Ulinski, T., Deschênes, G., Burtey, S., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030343 · Cited by 127
High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies
Bu, F., Borsa, N. G., Jones, M. B., Takanami, E., Nishimura, C. J., Hauer, J. J., Azaiez, H., Black-Ziegelbein, E. A., Meyer, N. C., Kolbe, D. L., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015040385 · Cited by 126
Self-citationAnti-factor B autoantibody in dense deposit disease
Strobel, S., Zimmering, M., Papp, K., Prechl, J., & Józsi, M. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.02.002 · Cited by 122
Self-citationProperdin: a tightly regulated critical inflammatory modulator
Blatt, A. Z., Pathan, S., & Ferreira, V. P. (2016) · Immunological Reviews · doi:10.1111/imr.12466 · Cited by 113
Csincsi, Á. I., Kopp, A., Zöldi, M., Bánlaki, Z., Uzonyi, B., Hebecker, M., Caesar, J. J. E., Pickering, M. C., Daigo, K., Hamakubo, T., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403121 · Cited by 111
Self-citationPersson, B. D., Schmitz, N., Santiago, C. A., Zocher, G., Larvie, M., Scheu, U., Casasnovas, J. M., & Stehle, T. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001122 · Cited by 109
Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy
Avasare, R. S., Canetta, P. A., Bomback, A. S., et al. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09080817 · Cited by 105
Clinical features and outcomes of 98 children and adults with dense deposit disease
Lu, D.-F., Moon, M., Lanning, L. D., McCarthy, A. M., & Smith, R. J. (2011) · Pediatric Nephrology · doi:10.1007/s00467-011-2059-7 · Cited by 99
Self-citationCombination of Factor H Mutation and Properdin Deficiency Causes Severe C3 Glomerulonephritis
Lesher, A. M., Zhou, L., Kimura, Y., Sato, S., Gullipalli, D., Herbert, A. P., Barlow, P. N., Eberhardt, H. U., Skerka, C., Zipfel, P. F., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012060570 · Cited by 92
Self-citationHuman Factor H-Related Protein 2 (CFHR2) Regulates Complement Activation
Eberhardt, H. U., Buhlmann, D., Hortschansky, P., Chen, Q., Böhm, S., Kemper, M. J., Wallich, R., Hartmann, A., Hallström, T., Zipfel, P. F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078617 · Cited by 91
Self-citationKidney Disease Caused by Dysregulation of the Complement Alternative Pathway
Vriese, A. S. D., Sethi, S. M., Praet, J. T. V., Nath, K. A., & Fervenza, F. C. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015020184 · Cited by 86
Self-citationLoss of Properdin Exacerbates C3 Glomerulopathy Resulting from Factor H Deficiency
Ruseva, M. M., Vernon, K. A., Lesher, A. M., Schwaeble, W., Ali, Y. M., Botto, M., Cook, T. H., Song, W., Stover, C. M., & Pickering, M. C. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012060571 · Cited by 79
Self-citationResolution of the three dimensional structure of components of the glomerular filtration barrier
Arkill, K. P., Qvortrup, K., Starborg, T., Mantell, J., Knupp, C., Michel, C. C., Harper, S. J., Salmon, A., Squire, J. M., Bates, D. O., et al. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-24 · Cited by 74
The complement factor H‐related proteins
Medjeral‐Thomas, N., & Pickering, M. C. (2016) · Immunological Reviews · doi:10.1111/imr.12477 · Cited by 71
Self-citationHyperlipidemia and thrombotic complications in patients with membranous nephropathy
Nickolas, T. L., Radhakrishnan, J., & Appel, G. B. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00058-5 · Cited by 61
Self-citationChen, Q., Manzke, M., Hartmann, A., Büttner, M., Amann, K., Pauly, D., Wiesener, M. S., Skerka, C., & Zipfel, P. F. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015020212 · Cited by 59
Self-citationFamilial C3 glomerulonephritis caused by a novel CFHR5-CFHR2 fusion gene
Xiao, X., Ghossein, C., Tortajada, A., Zhang, Y., Meyer, N. C., Jones, M. P., Borsa, N. G., Nester, C., Thomas, C. P., de Córdoba, S. R., et al. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.07.007 · Cited by 53
Self-citationC3 glomerulopathy: what's in a name?
D’Agati, V. D., & Bomback, A. S. (2012) · Kidney International · doi:10.1038/ki.2012.80 · Cited by 50
Self-citationComplement inhibition in C3 glomerulopathy
Nester, C., & Smith, R. J. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.06.002 · Cited by 45
Self-citationA novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy
Togarsimalemath, S. K., Sethi, S. K., Duggal, R., Quintrec, M. L., Jha, P. K., Daniel, R., Gonnet, F., Bansal, S. B., Roumenina, L. T., Frémeaux‐Bacchi, V., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.04.025 · Cited by 42
Self-citationLloyd, I. E., Gallan, A. J., Huston, H. K., Raphael, K. L., Miller, D. V., Revelo, M. P., & Khalighi, M. A. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfw090 · Cited by 37
Loeven, M. A., Rops, A. L. W. M. M., Lehtinen, M. J., Kuppevelt, T. H. V., Daha, M. R., Smith, R. J., Bakker, M. A. H., Berden, J. H. M., Rabelink, T. J., Jokiranta, T. S., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.702506 · Cited by 25
Self-citation
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationInnate immunity in diabetic kidney disease
Tang, S. C. W., & Yiu, W. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0234-4 · Cited by 596
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Self-citationA guide to complement biology, pathology and therapeutic opportunity
Mastellos, D. C., Hajishengallis, G., & Lambris, J. D. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00926-1 · Cited by 320
Self-citationCrosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation
Bekassy, Z., Lopatko Fagerström, I., Bader, M., & Karpman, D. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-021-00634-8 · Cited by 167
Metadata
- Authors
- Smith, R. J. H., Appel, G. B., Blom, A. M., Cook, H. T., D’Agati, V. D., Fakhouri, F., Fremeaux-Bacchi, V., Józsi, M., Kavanagh, D., Lambris, J. D., Noris, M., Pickering, M. C., Remuzzi, G., de Córdoba, S. R., Sethi, S., Van der Vlag, J., Zipfel, P. F., & Nester, C. M.
- Venue
- Nature Reviews Nephrology
- Published
- 2019-01-28
- Volume
- 15
- Issue
- 3
- Pages
- 129-143
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- OpenAlex
- W2914604561
- Cited by
- 409
- References
- 64
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.